Financial Ratios QuidelOrtho Corporation
Equities
QDEL
US2197981051
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.10 USD | -4.58% |
|
-17.91% | -40.13% |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 26.61 | 10.99 | 2.01 | 0.65 | 1.27 | |||||
Return on Total Capital | 32.62 | 12.58 | 2.27 | 0.73 | 1.48 | |||||
Return On Equity % | 43.18 | 15.99 | -0.2 | -51.36 | -46.15 | |||||
Return on Common Equity | 43.18 | 15.99 | -0.2 | -51.36 | -46.15 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 74.82 | 59.28 | 49.85 | 46.23 | 46.81 | |||||
SG&A Margin | 15.27 | 19.01 | 25.46 | 27.55 | 27.33 | |||||
EBITDA Margin % | 57.06 | 39.03 | 24.56 | 18.98 | 20.58 | |||||
EBITA Margin % | 55.47 | 34.4 | 16.14 | 10 | 11.33 | |||||
EBIT Margin % | 53.92 | 30.37 | 9.33 | 2.79 | 4.53 | |||||
Income From Continuing Operations Margin % | 41.46 | 16.8 | -0.34 | -73.74 | -41.45 | |||||
Net Income Margin % | 41.46 | 16.8 | -0.34 | -73.74 | -41.45 | |||||
Net Avail. For Common Margin % | 41.46 | 16.8 | -0.34 | -73.74 | -41.45 | |||||
Normalized Net Income Margin | 33.49 | 17.38 | 2.32 | -2.09 | -1.37 | |||||
Levered Free Cash Flow Margin | 22.43 | 19.59 | 11.21 | 7.61 | 8.57 | |||||
Unlevered Free Cash Flow Margin | 22.62 | 21.06 | 15.01 | 11.91 | 12.87 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.79 | 0.58 | 0.34 | 0.37 | 0.45 | |||||
Fixed Assets Turnover | 4.94 | 3.27 | 1.91 | 1.76 | 1.78 | |||||
Receivables Turnover (Average Receivables) | 3.81 | 7.41 | 7.03 | 8.38 | 7.12 | |||||
Inventory Turnover (Average Inventory) | 2.74 | 3.68 | 2.73 | 2.69 | 2.61 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 4.45 | 1.56 | 1.57 | 1.22 | 1.5 | |||||
Quick Ratio | 3.78 | 0.94 | 0.79 | 0.55 | 0.77 | |||||
Operating Cash Flow to Current Liabilities | 2.49 | 0.88 | 0.34 | 0.08 | 0.11 | |||||
Days Sales Outstanding (Average Receivables) | 95.81 | 49.12 | 51.79 | 43.45 | 51.1 | |||||
Days Outstanding Inventory (Average Inventory) | 133.38 | 98.92 | 133.39 | 135.19 | 139.28 | |||||
Average Days Payable Outstanding | 66.86 | 42.31 | 67.57 | 67.77 | 63.91 | |||||
Cash Conversion Cycle (Average Days) | 162.33 | 105.74 | 117.61 | 110.87 | 126.46 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 7.22 | 57.78 | 52.36 | 89.84 | 148.6 | |||||
Total Debt / Total Capital | 6.73 | 36.62 | 34.37 | 47.33 | 59.77 | |||||
LT Debt/Equity | 6.68 | 53.08 | 49.03 | 77.35 | 137.79 | |||||
Long-Term Debt / Total Capital | 6.23 | 33.64 | 32.18 | 40.74 | 55.43 | |||||
Total Liabilities / Total Assets | 20.61 | 44.28 | 41.54 | 53.54 | 66.71 | |||||
EBIT / Interest Expense | 160.5 | 12.95 | 1.53 | 0.41 | 0.66 | |||||
EBITDA / Interest Expense | 172.55 | 17.06 | 4.31 | 3.04 | 3.24 | |||||
(EBITDA - Capex) / Interest Expense | 121.25 | 15.22 | 3.16 | 2.02 | 2.24 | |||||
Total Debt / EBITDA | 0.14 | 2.18 | 3.34 | 4.61 | 4.68 | |||||
Net Debt / EBITDA | -0.74 | 1.89 | 3.12 | 4.44 | 4.4 | |||||
Total Debt / (EBITDA - Capex) | 0.2 | 2.45 | 4.56 | 6.93 | 6.78 | |||||
Net Debt / (EBITDA - Capex) | -1.05 | 2.12 | 4.25 | 6.67 | 6.37 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 2.22 | 92.28 | -8.21 | -7.17 | -1.89 | |||||
Gross Profit, 1 Yr. Growth % | -5.78 | 51.45 | -22.81 | -14.07 | -0.66 | |||||
EBITDA, 1 Yr. Growth % | -12.97 | 31.78 | -42.25 | -28.68 | 12.92 | |||||
EBITA, 1 Yr. Growth % | -13.7 | 19.28 | -56.94 | -43.01 | 24.83 | |||||
EBIT, 1 Yr. Growth % | -14.04 | 8.34 | -71.81 | -72.69 | 162.98 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -13.09 | -22.08 | -101.84 | 20.22K | -44.84 | |||||
Net Income, 1 Yr. Growth % | -13.09 | -22.08 | -101.84 | 20.22K | -44.84 | |||||
Normalized Net Income, 1 Yr. Growth % | -13.89 | -0.19 | -87.73 | -180.24 | -51.62 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -11.66 | -41.81 | -101.58 | 20.1K | -45.34 | |||||
Accounts Receivable, 1 Yr. Growth % | -26.43 | 33.2 | -30.59 | -9.9 | 43.44 | |||||
Inventory, 1 Yr. Growth % | 74.66 | 163.63 | 10.25 | -7.63 | 8.23 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 125.96 | 218.79 | 6.14 | -4 | -2.27 | |||||
Total Assets, 1 Yr. Growth % | 29.89 | 264.38 | -3.31 | -24.99 | -10.19 | |||||
Tangible Book Value, 1 Yr. Growth % | 71.05 | -144.59 | -36.88 | -4.71 | 60.58 | |||||
Common Equity, 1 Yr. Growth % | 44.77 | 155.76 | 1.44 | -40.38 | -35.65 | |||||
Cash From Operations, 1 Yr. Growth % | 27.96 | 9.85 | -68.35 | -70.38 | 26.75 | |||||
Capital Expenditures, 1 Yr. Growth % | 350.85 | -51.88 | 48.54 | -6.78 | -3.54 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -6.12 | 67.6 | -47.5 | -37.48 | 21.38 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -6.39 | 79.94 | -34.6 | -26.77 | 12.44 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 78.2 | 40.19 | 32.85 | -7.69 | -4.57 | |||||
Gross Profit, 2 Yr. CAGR % | 99.04 | 19.47 | 8.12 | -18.49 | -7.61 | |||||
EBITDA, 2 Yr. CAGR % | 151.79 | 7.07 | -12.76 | -35.69 | -11.26 | |||||
EBITA, 2 Yr. CAGR % | 166.62 | 1.51 | -28.33 | -50.29 | -18.12 | |||||
EBIT, 2 Yr. CAGR % | 194.15 | -3.44 | -44.74 | -72.07 | -30.65 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 210.76 | -17.71 | -88.02 | 93.38 | 958.58 | |||||
Net Income, 2 Yr. CAGR % | 210.76 | -17.71 | -88.02 | 93.38 | 958.58 | |||||
Normalized Net Income, 2 Yr. CAGR % | 216.15 | -7.19 | -65.01 | -68.05 | -17.94 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 207.79 | -28.3 | -90.41 | 78.73 | 950.75 | |||||
Accounts Receivable, 2 Yr. CAGR % | 100 | -1 | -3.84 | -20.92 | 13.68 | |||||
Inventory, 2 Yr. CAGR % | 84.98 | 114.6 | 70.48 | 0.91 | -0.02 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 66.56 | 168.38 | 83.95 | 0.95 | -3.14 | |||||
Total Assets, 2 Yr. CAGR % | 63.35 | 117.55 | 87.71 | -14.83 | -17.92 | |||||
Tangible Book Value, 2 Yr. CAGR % | 347.2 | -12.67 | -46.95 | -22.44 | 23.7 | |||||
Common Equity, 2 Yr. CAGR % | 85.64 | 92.42 | 61.08 | -22.23 | -38.06 | |||||
Cash From Operations, 2 Yr. CAGR % | 144.79 | 18.57 | -41.04 | -69.38 | -38.73 | |||||
Capital Expenditures, 2 Yr. CAGR % | 227.88 | 47.34 | -15.45 | 17.67 | -5.17 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 126.82 | 25.12 | -6.19 | -42.55 | -14.76 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 116.82 | 29.64 | 8.48 | -30.66 | -10.22 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 48.16 | 82.78 | 21.74 | 17.89 | -5.8 | |||||
Gross Profit, 3 Yr. CAGR % | 58.47 | 82.06 | 3.28 | 0.21 | -12.93 | |||||
EBITDA, 3 Yr. CAGR % | 82.23 | 102.78 | -12.84 | -18.26 | -23.95 | |||||
EBITA, 3 Yr. CAGR % | 87.61 | 103.9 | -23.73 | -33.4 | -35.01 | |||||
EBIT, 3 Yr. CAGR % | 99.76 | 110.83 | -35.95 | -56.07 | -50.1 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 111.74 | 95.96 | -76.81 | 42.83 | 27.3 | |||||
Net Income, 3 Yr. CAGR % | 111.74 | 95.96 | -76.81 | 42.83 | 27.3 | |||||
Normalized Net Income, 3 Yr. CAGR % | 115.76 | 115.25 | -52.73 | -53.24 | -59.66 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 106.75 | 76.65 | -79.89 | 22.95 | 20.42 | |||||
Accounts Receivable, 3 Yr. CAGR % | 86.06 | 74.66 | -12.05 | -5.91 | -3.55 | |||||
Inventory, 3 Yr. CAGR % | 43.42 | 108.18 | 71.88 | 38.98 | 3.29 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 86.17 | 106.79 | 97 | 48.1 | -0.14 | |||||
Total Assets, 3 Yr. CAGR % | 44.45 | 113.43 | 66.02 | 38.26 | -13.31 | |||||
Tangible Book Value, 3 Yr. CAGR % | 158.51 | 107.37 | -21.63 | -35.51 | -1.15 | |||||
Common Equity, 3 Yr. CAGR % | 65.5 | 106.57 | 55.45 | 15.65 | -26.99 | |||||
Cash From Operations, 3 Yr. CAGR % | 80.8 | 87.42 | -23.66 | -53.13 | -50.84 | |||||
Capital Expenditures, 3 Yr. CAGR % | 109.82 | 72.97 | 47.74 | -12.66 | 10.13 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 18.41 | 105.21 | -6.33 | -17.83 | -28.57 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 16.86 | 103.41 | 3.2 | -4.64 | -20.14 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 54.72 | 63.71 | 41.83 | 39.07 | 10.44 | |||||
Gross Profit, 5 Yr. CAGR % | 62.77 | 63.24 | 36.16 | 32.02 | -1.18 | |||||
EBITDA, 5 Yr. CAGR % | 121.48 | 80.31 | 35.67 | 28.15 | -12.76 | |||||
EBITA, 5 Yr. CAGR % | 187.62 | 84.73 | 27.66 | 15.99 | -22.28 | |||||
EBIT, 5 Yr. CAGR % | 193.39 | 93.12 | 19.47 | -6.02 | -34.98 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 119.54 | 131.99 | -32.89 | 94.92 | 6.91 | |||||
Net Income, 5 Yr. CAGR % | 119.54 | 131.99 | -32.89 | 94.92 | 6.91 | |||||
Normalized Net Income, 5 Yr. CAGR % | 123.3 | 115.95 | 4.22 | 0.42 | -43.67 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 107.99 | 108.6 | -39.46 | 77.48 | -2.13 | |||||
Accounts Receivable, 5 Yr. CAGR % | 72.16 | 46.52 | 42.89 | 27.22 | -2.54 | |||||
Inventory, 5 Yr. CAGR % | 50.15 | 50.86 | 53.69 | 55.83 | 38.39 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 56.46 | 89.88 | 85.28 | 55.22 | 48.3 | |||||
Total Assets, 5 Yr. CAGR % | 44.32 | 56.77 | 60.41 | 47.8 | 25.26 | |||||
Tangible Book Value, 5 Yr. CAGR % | 75.72 | 16.25 | 37.2 | 39.92 | -5.93 | |||||
Common Equity, 5 Yr. CAGR % | 57.25 | 85.1 | 63.72 | 39.75 | 7.58 | |||||
Cash From Operations, 5 Yr. CAGR % | 132.68 | 99.94 | 15.5 | -9.2 | -30.08 | |||||
Capital Expenditures, 5 Yr. CAGR % | 89.72 | 51.75 | 45.87 | 48.27 | 23.73 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 102.12 | 38.79 | 7.92 | 23.39 | -10.57 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 96.79 | 41.96 | 13.32 | 32.32 | -3.01 |
- Stock Market
- Equities
- QDEL Stock
- Financials QuidelOrtho Corporation
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















